Treatment of XXXX in Japan -The current status and the future plan.

@entity1 @entity981 @entity706 @entity1892 @entity978
UNASSIGNED: Results of @entity706 treatment have improved markedly over the past 30 years. In @entity978 , the 5-year event-free survival (EFS) rate was 81.5% in a retrospective study. In the ALB-NHL03 study, the five-year EFS according to clinical stage in @entity1 with @entity981 was 70.6% for stage III and 88.9% for stage IV. In @entity1892 , the B-NHL03 study indicated that the 4-year EFS according to treatment group was 94% for Group 1, 98% for Group 2, 84% for Group 3, and 78% for Group 4 based on. Moreover, the two-year EFS rate was 81% in Japanese advanced stage @entity1 based on the international ALCL99 study. Thus, an EFS rate of over 80% was achieved in any subtype of @entity706 . However, @entity1 with refractory or recurrent @entity706 also exist and treatment methods for improvement of the survival rate of these @entity1 have to be developed. It's also a future problem to make the difference between the @entity1 and adolescent and young adult generation clear and develop treatment protocol. Although @entity706 treatment does not greatly change according to country, it does differ between other countries and Japan for some subtypes of @entity706 . In particular, the results of treatment of stage III T-LBL in Japan are worse than those of the US and European countries. It will be important to obtain evidence regarding these differences, and the reasons for these differences, in future studies. This article is protected by copyright. All rights reserved.
